

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

AMENDMENT NO. 3
TO
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

TFF PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware**2834****82-4344737**(State or other jurisdiction of
Incorporation or organization)(Primary Standard Industrial
Classification Code Number)(IRS Employer
Identification Number)

2600 Via Fortuna, Suite 360
Austin, Texas 78746
(737) 802-1973

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Glenn Mattes
President and Chief Executive Officer
TFF Pharmaceuticals, Inc.
2600 Via Fortuna, Suite 360
Austin, Texas 78746
(737) 802-1973

(Address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Daniel K. Donahue, Esq.
Christopher M. Piazza, Esq.
Greenberg Traurig, LLP
3161 Michelson Drive, Suite 1000
Irvine, California 92612
Telephone: (949) 732-6557

Kevin K. Leung, Esq.
Dominador D. Tolentino, Jr., Esq.
LKP Global Law, LLP
1901 Avenue of the Stars, Suite 480
Los Angeles, California 90067
Telephone: (424) 239-1890

Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer
Non-accelerated filer

Accelerated filer
Smaller reporting company
Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment, which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

EXPLANATORY NOTE

The sole purpose of this Amendment No. 3 (the “Amendment”) to the Registration Statement on Form S-1 (the “Registration Statement”) of TFF Pharmaceuticals, Inc. is to refile Exhibit 5.1 to the Registration Statement as indicated in Item 16(a) of Part II of this Amendment. No change is made to the preliminary prospectus constituting Part I of the Registration Statement or Items 13, 14, 15, 16(b) or 17 of Part II of the Registration Statement. Accordingly, this Amendment consists only of the facing page, this explanatory note and Item 16(a) of Part II, including Exhibit 5.1, and the signature page of the Registration Statement.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 16. EXHIBITS

Exhibit No.	Description of Document
1.1*	Form of Underwriting Agreement
3.1*	Second Amended and Restated Certificate of Incorporation of the Registrant
3.2*	Bylaws of the Registrant
3.3*	Amended and Restated Bylaws of the Registrant effective immediately following the closing of this offering
4.1*	Specimen Certificate representing shares of common stock of Registrant
4.2*	Warrant dated January 24, 2018 issued to Liquid Patent Advisors, LLC
4.3*	Warrant dated March 13, 2018 issued to National Securities Corporation
4.4*	Warrant dated March 22, 2018 issued to National Securities Corporation
4.5*	Warrant dated May 16, 2019 issued to National Securities Corporation
4.6*	Warrant dated May 23, 2019 issued to National Securities Corporation
5.1	Opinion of Greenberg Traurig, LLP regarding the validity of the common stock being registered
10.1*	Engagement Agreement dated January 26, 2018 between Liquid Patent Advisors, LLC and the Registrant
10.2*	Securities Purchase Agreement dated March 13, 2018 by and among the Registrant and the Buyers named therein
10.3*	Amended and Restated Registration Rights Agreement dated May 16, 2019 by and among the Registrant and certain of its stockholders
10.4*	Contribution and Subscription Agreement dated January 24, 2018 between the Registrant and Lung Therapeutics, Inc.
10.5*	Patent License Agreement dated July 8, 2015 between Lung Therapeutics, Inc. and The University of Texas at Austin
10.6*+	TFF Pharmaceuticals, Inc. 2018 Stock Incentive Plan
10.7*+	Amended and Restated Consulting Agreement dated December 20, 2018 between Robert Mills and the Registrant
10.8*+	Consulting Agreement effective as of January 24, 2018 between Dr. Brian Windsor and the Registrant, as amended on December 20, 2018 and September 26, 2019
10.9*+	Consulting Agreement dated April 23, 2018 between Glenn Mattes and the Registrant

Exhibit No.	Description of Document
10.10*	Lease Agreement dated October 19, 2018
10.11*+	Executive Employment Agreement dated December 20, 2018 between Glenn Mattes and the Registrant
10.12*	Securities Purchase Agreement dated May 16, 2019 by and among the Registrant and the Buyers named therein
10.13*	Amendment No. 1 to Patent License Agreement dated November 30, 2018 between the Registrant and The University of Texas at Austin
10.14*+	Employment Agreement, dated February 15, 2019, by and between the Registrant and Kirk Coleman
21.1*	List of Subsidiaries
23.1*	Consent of Marcum LLP, Independent Registered Public Accounting Firm
23.2	Consent of Greenberg Traurig, LLP (included in Exhibit 5.1)
24.1*	Power of Attorney.

* Previously filed

+ Indicates management compensatory plan, contract or arrangement

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Austin, Texas on this 11th day of October 2019.

TFF PHARMACEUTICALS, INC.

/s/ Glenn Mattes

Glenn Mattes
Chief Executive Officer and Director
(Principal Executive Officer)

Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Glenn Mattes</u> Glenn Mattes	President, Chief Executive Officer and Director <i>(Principal Executive Officer)</i>	October 11, 2019
<u>/s/ Kirk Coleman</u> Kirk Coleman	Chief Financial Officer, Treasurer and Secretary <i>(Principal Financial and Accounting Officer)</i>	October 11, 2019
<u>*</u> Aaron Fletcher, Ph.D.	Chairman of the Board	October 11, 2019
<u>*</u> Brian Windsor, Ph.D.	Director	October 11, 2019
<u>*</u> Robert S. Mills, Jr.	Director	October 11, 2019
<u>*</u> Stephen C. Rocamboli	Director	October 11, 2019
<u>*</u> Harlan Weisman, M.D.	Director	October 11, 2019
<u>*</u> Randy Thurman	Director	October 11, 2019
<u>*By: /s/ Glenn Mattes</u> Glenn Mattes Attorney-in-Fact		

GREENBERG TRAURIG, LLP
3161 Michelson Drive, Suite 1000
Irvine, California 92612

October 11, 2019

TFF Pharmaceuticals, Inc.
2600 Via Fortuna, Suite 360
Austin, Texas 78746

Re: Registration Statement on Form S-1

Ladies and Gentlemen:

We have acted as counsel to TFF Pharmaceuticals, Inc., a Delaware corporation (the “**Company**”), in connection with the Registration Statement on Form S-1 (File No. 333-233378) (the “**Registration Statement**”) filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended, for the registration of (i) up to 5,060,000 shares (the “**Common Shares**”) of the Company’s \$0.001 par value common stock (“**Common Stock**”); (ii) a warrant to purchase up to 328,900 shares of Common Stock to be issued to the underwriter (the “**Underwriter’s Warrant**”); and (iii) up to 328,900 shares of Common Stock underlying the Underwriter’s Warrant (the “**Underlying Shares**”).

You have requested our opinion as to the matters set forth below in connection with the Registration Statement. For purposes of rendering this opinion, we have examined the Registration Statement, forms of the Second Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws of the Company currently in effect, the Underwriter’s Warrant, and the corporate action of the Company that provides for the issuance of the Common Shares and execution of the Underwriter’s Warrant, and we have made such other investigation as we have deemed appropriate. We have examined and relied upon certificates of public officials and, as to certain matters of fact that are material to our opinion, we have also relied on a certificate of an officer of the Company. We have not independently verified the matters set forth in such certificates.

We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware, the laws of the State of New York and the federal laws of the United States of America.

Based upon and subject to the foregoing, it is our opinion that the Common Shares are duly authorized for issuance by the Company and, when issued and paid for as described in the Registration Statement, will be validly issued, fully paid and non-assessable.

Based upon and subject to the foregoing, it is our opinion that the Underwriter’s Warrant has been duly authorized for issuance by the Company and, when issued in conformity with and pursuant to the Registration Statement, will be validly issued, fully paid and non-assessable, and will be a valid and legally binding obligation of the Company in accordance with its terms under the laws of the State of New York.

Based upon and subject to the foregoing, it is our opinion that the Underlying Shares have been duly authorized for issuance by the Company and, upon exercise and payment of the exercise price therefor in accordance with the terms of the Underwriter’s Warrant, will be validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our name under the caption “Legal Matters” in the prospectus made part of the Registration Statement.

Very truly yours,

/s/ GREENBERG TRAURIG, LLP